Hepatitis C virus and HIV infections among people who inject drugs in the Middle East and North Africa: A neglected public health burden?

Journal of the International AIDS Society

Volumn 18, Issue 1, 2015, Pages

  Mumtaz, Ghina R ^a,b   Weiss, Helen A ^b   Abu Raddad, Laith J ^a,c  

^a Infectious Disease Epidemiology Group Weill Cornell Medical College Qatar Cornell University Qatar Foundation Education City ^*  (Qatar)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG ABUSE; DRUG USE; EDUCATION; EMPLOYMENT; EPIDEMIC; HARM REDUCTION; HEALTH CARE ACCESS; HEALTH CARE SYSTEM; HEALTH HAZARD; HEPATITIS C; HEPATITIS C VIRUS; HIV TEST; HOMELESSNESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; MIDDLE EAST; MOROCCO; NAMED GROUPS OF PERSONS; NORTH AFRICA; NOTE; PAKISTAN; PEOPLE WHO INJECT DRUG; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; SCALE UP; SEXUAL PRACTICE; SOCIAL STIGMA; AFRICA; COMPLICATION; HIV INFECTIONS; INCIDENCE; PUBLIC HEALTH; SUBSTANCE ABUSE;

AFRICA, NORTHERN; HEPATITIS C; HIV INFECTIONS; HUMANS; INCIDENCE; MIDDLE EAST; PUBLIC HEALTH; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84938248173     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.18.1.20582     Document Type: Note

References (20)

1. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378(9791):571-83. doi: 10.1016/S0140-6736(11)61097-0.
2. Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372(9651):1733-45. doi: 10.1016/S0140-6736(08)61311-2.
3. Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy. 2007;18(5):352-8. doi: 10.1016/j.drugpo. 2007.04.004.
4. UNODC. United Nations Office on Drugs and Crime. World Drug Report [Internet]. 2011 [cited 2015 Jul]. Available from: http://www.unodc.org/documents/data-And-Analysis/WDR2011/World-Drug-Report-2011-ebook.pdf
5. Abu-Raddad L, Akala FA, Semini I, Riedner G, Wilson D, Tawil O. Characterizing the HIV/AIDS epidemic in the Middle East and North Africa: time for strategic action. Middle East and North Africa HIV/AIDS Epidemiology Synthesis Project.World Bank/UNAIDS/WHO Publication. Washington, DC: The World Bank Press; 2010.
6. Mumtaz GR, Weiss HA, Thomas SL, Riome S, Setayesh H, Riedner G, et al. HIV among people who inject drugs in the Middle East and North Africa: systematic review and data synthesis. PLoS Med. 2014;11(6):e1001663. doi: 10.1371/journal.pmed.1001663.
7. Lansky A, Finlayson T, Johnson C, Holtzman D, Wejnert C, Mitsch A, et al. Estimating the number of persons who inject drugs in the United States by meta-Analysis to calculate national rates of HIV and hepatitis C virus infections. PLoS One. 2014;9(5):e97596. doi: 10.1371/journal.pone.0097596.
8. Todd C, Nasir A, Stanekzai MR, Rasuli MZ, Fiekert, Orr M, et al. Hepatitis C and HIV incidence among injecting drug users in Kabul, Afghanistan. Abstract no. MOPDC101. AIDS 2010-XVIII International AIDS Conference; Vienna, Austria; 18-23 July 2010.
9. Mirzoyan L, Berendes S, Jeffery C, Thomson J, Ben Othman H, Danon L, et al. New evidence on the HIV epidemic in Libya: why countries must implement prevention programs among people who inject drugs. J Acquir Immune Defic Syndr. 2013;62(5):577-83. doi: 10.1097/QAI.0b013e318284714a.
10. Hadi DHMH, Shujaat PDMGSH, Waheed PDWUZ, Masood PDMGMA. Incidence of hepatitis C virus and HIV among injecting drug users in Northern Pakistan: a prospective cohort study. Abstract no. MoOa0104. IAS 2005-The 3rd IAS Conference on HIV Pathogenesis and Treatment; Rio de Janeiro, Brazil; 24-27 July 2005.
11. Jahani MR, Kheirandish P, Hosseini M, Shirzad H, Seyedalinaghi SA, Karami N, et al. HIV seroconversion among injection drug users in detention, Tehran, Iran. AIDS. 2009;23(4):538-40. doi: 10.1097/QAD.0b013e3283269e3c.
12. Gouws E, Cuchi P, on behalf of the International Collaboration on Estimating HIV Incidence by Modes of Transmission (including Laith J. Abu-Raddad and Ghina R. Mumtaz). Focusing the HIV response through estimating the major modes of HIV transmission: a multi-country analysis. Sex Transm Infect. 2012;88(Suppl 2):i76-85. doi: 10.1136/sextrans-2012-050719.
13. Mumtaz GR, Weiss HA, Vickerman P, Larke N, Abu-Raddad LJ. Using hepatitis C prevalence to estimate HIV epidemic potential among people who inject in the Middle East and North Africa. AIDS. 2015.
14. Harm Reduction International. The global state of harm reduction 2012: towards an integrated response [Internet]. 2014 [cited 2015 Jul 2]. Available from: http://www.ihra.net/files/2015/02/16/GSHR2014.pdf
15. Krug A, Hildebrand M, Sun N. ''We don't need services. We have no problems'': exploring the experiences of young people who inject drugs in accessing harm reduction services. J Int AIDS Soc. 2015;18(2 Suppl 1):19442, doi: http://dx.doi.org/10.7448/IAS.18.2.19442
16. Kamal-Yanni M. Hepatitis C drug affordability. Lancet Global Health. 2015;3(2):e73-4. doi: 10.1016/S2214-109X(14)70365-1.
17. Jules Levin. Minimum costs to produce Hepatitis C Direct Acting Antivirals for access programs in developing countries. 64th Annual Meeting of AASLD, Washington, DC; 2013 Nov. [Poster 1097].
18. World Health Organization Regional Office for the Eastern Mediterranean. Antiretroviral therapy coverage [Internet]. [cited 2015 Jul]. Available from: http://apps.who.int/gho/data/node.main.626?lang-en
19. Alkaiyat A, Weiss MG. HIV in the Middle East and North Africa: priority, culture, and control. Int J Public Health. 2013;58(6):927-37. doi: 10.1007/s00038-013-0485-y.
20. Ford N, Wiktor S, Kaplan K, Andrieux-Meyer I, Hill A, Radhakrishnan P, et al. Ten priorities for expanding access to HCV treatment for people who inject drugs in low-And middle-income countries. Int J Drug Policy. 2015. doi: 10.1016/j.drugpo.2015.05.004.